Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Coherus BioSciences, Inc., a leading biotechnology firm headquartered in the United States, focuses on the development and commercialisation of innovative biologic therapies. Founded in 2010, the company has made significant strides in the biosimilars market, particularly in oncology and autoimmune diseases.
With a robust portfolio that includes products like Udenyca, Coherus stands out for its commitment to providing high-quality, cost-effective alternatives to expensive biologic treatments. The company operates primarily in North America, with a growing presence in international markets.
Recognised for its scientific expertise and strategic partnerships, Coherus BioSciences has established a strong market position, contributing to the accessibility of essential therapies for patients worldwide.
-19 vs industry average
Coherus BioSciences, Inc.’s score of 23 is lower than 33% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
No reported emissions data is available for Coherus BioSciences, Inc. yet.
Coherus BioSciences, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company.
As of now, Coherus BioSciences has not inherited any emissions data from a parent or related organization, and there are no climate initiatives or commitments reported through recognised frameworks such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP).
In the context of the biopharmaceutical industry, companies are increasingly focusing on sustainability and carbon reduction strategies. However, without specific data or commitments from Coherus BioSciences, it is unclear how they align with these industry trends.
No climate goals have been disclosed for Coherus BioSciences, Inc. yet.
No scope 3 category breakdown has been disclosed yet.


No peer comparison is available for Coherus BioSciences, Inc. yet.
PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more